Interactive Response Technology (IRT) earns its place in a study by doing three jobs at once. It records who is enrolled and which arm they belong to. It keeps the right study drug at the right sites before it expires. And it does both without letting blinded staff learn what any participant is receiving. Each job is simple on paper. The difficulty is that they depend on each other, and a weak spot in one shows up as a problem in another.
Three jobs that share one set of records
The reason sponsors centralize these functions in one system is that each transaction touches more than one job. When a coordinator randomizes a participant, the system must pick an arm, check that a matching kit is available at that site, assign a kit number that does not reveal the arm, and decrement inventory. If those steps lived in separate tools, every handoff would be a chance for error or for an accidental unblinding.
Job one: enrollment and randomization
At a screening visit, the site registers the participant in IRT. The system may ask eligibility questions defined by the protocol, then hold the participant in a screened status until the site confirms enrollment.
At randomization, IRT applies the sponsor’s scheme. In a simple design, that may be a fixed allocation list. In more complex designs, it may account for stratification factors such as age group or disease severity, caps on how many participants can enter a cohort, or dose escalation rules that open a new cohort only after a safety review.
What the site sees is usually a confirmation with a participant number, a randomization date, and a kit number to dispense. What the site does not see is the arm, unless the study is open label.
Practical checks for enrollment workflows
- Are screen failures recorded consistently so enrollment reports stay accurate?
- If a cohort cap is reached, what message does the site see, and who is notified?
- Is there a documented process when a site randomizes the wrong participant by mistake?
Job two: study drug supply
Supply is where IRT does much of its quiet work. The system tracks inventory at central depots and at each site, including lot numbers and expiry dates. It can trigger a resupply shipment when site stock falls below a set level, and it can hold back kits that will expire before a participant’s next visit.
Typical supply activities include:
- Initial site shipments sized to expected early enrollment.
- Automated resupply based on thresholds the supply team defines.
- Shipment receipt where sites confirm what arrived and flag damaged or temperature-excursion kits.
- Expiry management so kits close to their date are not dispensed or are moved where they can be used.
- Returns and reconciliation so every kit is accounted for at study close.
Forecasting sits alongside these activities. Supply planners use enrollment pace and visit schedules to estimate how much drug to produce and where to position it. IRT provides the actual usage data that makes those forecasts more grounded over time.
Where supply issues usually start
Supply surprises often trace back to assumptions set at startup: resupply thresholds copied from a different study, visit windows that do not match the protocol, or sites that receive shipments without confirming them in the system. None of these are technology failures. They are configuration and training gaps worth reviewing early.
Job three: blind protection
In a blinded study, the integrity of the result depends on participants, sites, and most sponsor staff not knowing treatment assignments. IRT supports that in several ways.
Role-based access. Blinded users see kit numbers and dates. Unblinded users, such as an independent pharmacist or a designated supply manager, may see more, depending on the study design.
Neutral kit numbering. Kit numbers are assigned so they do not hint at the arm. Two participants on different arms receive kits that look identical in the system and on the shelf.
Emergency unblinding. When a participant’s medical care requires knowing their treatment, an authorized investigator can unblind that one participant through a controlled process. The system typically records who requested it, when, and why, and notifies the appropriate sponsor contacts.
Blind risks outside IRT
The blind can also be put at risk by tools that have nothing to do with randomization. A participant reminder that mentions a dose strength, a diary question that only makes sense for one arm, or a report that groups data by kit type can all leak information. Our article on collecting patient-reported outcomes without breaking the blind covers what to check in participant-facing workflows.
Reporting ties the jobs together
Study managers rely on IRT reports to see enrollment by site, dispensing history, inventory levels, and upcoming expiries. Monitors use them to reconcile what the system says against what is on site. Because each record carries a time stamp and user, these reports also form part of the study’s audit trail.
How participant-facing data connects
IRT events often drive what happens next for the participant. A randomization date may start a diary schedule. A dispensing visit may trigger medication adherence check-ins by phone or text. Those participant-facing steps usually live in a separate ePRO or eCOA tool.
IVR Lab builds that participant-facing layer: ePRO and diaries for clinical trials, PROMIS administration, phone and SMS check-ins, and secure portal capture, with custom integrations to a sponsor’s or CRO’s EDC and randomization systems. If you are planning how participant data should follow IRT events, reach out to our team.

